Ticlopidine treatment reduced the need for vascular reconstructive surgery by about half , both in intention-to-treat and on-treatment analyses ( unadjusted relative risks 0.486 , 95 % CI 0.317-0 .745 ; p < 0.001 ; 0.493 , 95 % CI 0.290-0 .841 : p < 0.01 , respectively ) .
